You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Ontario Health (Cancer Care Ontario) Endorsement of ASCO Rapid Recommendation on 177Lutetium-Prostate-Specific Membrane Antigen-617 (PSMA-617) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

ID: GL-END 3-25 Nov 2023
Type of Content: Guidelines & Advice, Advice Report
Document Status: Current
K. Zukotynski, C. Arinze, G. Kulkarni, S. Hotte, A. Loblaw, Genitourinary Disease Site Group


The objectives of this guideline are to provide guidance for the most contemporary management for men with metastatic castration-resistant prostate cancer (mCRPC) and optimize treatment.

Patient Population

Patients with prostate cancer who are eligible for treatment with 177Lutetium-prostate-specific membrane antigen-617 (177Lutetium-PSMA-617).

Intended Guideline Users

This guideline is targeted for clinicians involved in the care of patients with prostate cancer who are eligible for treatment with 177Lutetium-PSMA-617.

pdf download Full Report (PDF) (399.09 KB)